Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Desaubry L, Robert C, Vagner S (2014) eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer...
The combination treatment with BRAF- and MEK-inhibitors is amongst the current standard of care for stage IIIC/IV BRAF-mutated melanoma. However, therapeutic options are limited once patients have progressed upon both targeted and immunotherapy. To investigate whether retreatment with BRAF- and MEK-...
BRAF V600E突变的CRC侵染性较强,预后差,单纯化疗 w/o anti-EGFR的疗效都很差,直至BRAF V600E抑制剂vemurafenib和dabrafenib单药获批BRAF突变的晚期黑色素瘤,并在携带该突变的肺癌、甲状腺癌等其他肿瘤中也显示了疗效,为CRC的治疗带来希望。最早是vemurafenib在表达BRAF V600E的CRC细胞系和PDX模型中证明可以阻滞癌细...
kg in HCT116 colorectal tumour xenograft models, consist- ent with previous unpublished studies using WX-554 and published studies using other MEK inhibitors that reported tumour growth delay or stasis in vivo, with increased sen- sitivity in BRAF or RAS mutant cells and tumours [3–5, 25]...
Fig. 1: In vitro potency of MEK and PI3K inhibitors against syngeneic tumor cell lines. ATP-based assessment of tumor cell viability in presence of indicated concentrations of small molecule inhibitors. Relative cell viability normalized to medium control. Inhibitory concentration (IC) 50 values calcu...
53.上期回顾:在《Anti-PD-(L)1联合用药策略》中集里,我们聚焦于肿瘤免疫周期的中间两个阶段:渗入和破境。涉及的靶向途径有TGFβ、VEGF/VEGFR、腺苷、MDSC、TAM、LILRB2、Treg、BRAF和MEK等。在本集里,我们将讨论肿瘤免疫周期的最后阶段:歼灭。 54.在...
Clin Cancer Res 16: 1613 – 1623 Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE (2005) Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 24: 3459 – 3471 & 2012 Cancer Research UK British ...
et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109, E2127–E2133 (2012). 39. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers ...
doi: 10.7150/ijbs.10745 MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer Yansong Bian1#, Jiawei Han1,2#, Vishnu Kannabiran1,3#, Suresh Mohan1,3, Hui Cheng1, Jay Friedman1, Luo Zhang2, Carter VanWaes1, ...
“This finding is suggestive of the additive antitumor effect of combining a BRAF inhibitor and a MEK inhibitor with immunotherapy, as demonstrated in an animal model.” The small numbers of patients in the individual treatment categories precluded attempts to discern differences in outcome...